OverviewSuggest Edit

Cue Biopharma is an immunotherapy company developing biologics engineered to selectively modulate disease-relevant T cells for the treatment of cancer and autoimmune disease. Cue biologics generate tailored immune responses in disease-relevant T cell populations by emulating the signals, or cues, delivered by the body’s antigen presenting cells (APCs), and can potentially address any T cell-mediated disease. Through this platform approach, the Company has developed a portfolio of promising drug candidates with two lead programs currently approaching the clinic.
TypePublic
Founded2015
HQCambridge, MA, US
Websitecuebiopharma.com

Latest Updates

Employees (est.) (Dec 2018)46(+65%)
Revenue (FY, 2020)$3.2 M(-8%)
Share Price (Sept 2021)$14.9(+6%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Cue Biopharma

Dan Passeri

Dan Passeri

Chief Executive Officer & Director
Frank Morich

Frank Morich

Chairman of the Board
Anish Suri

Anish Suri

Chief Scientific Officer, President
Kenneth Pienta

Kenneth Pienta

Acting Chief Medical Officer
Colin Sandercock

Colin Sandercock

Senior Vice President and General Counsel
Kerri-Ann Millar

Kerri-Ann Millar

Chief Financial Officer
Show more

Cue Biopharma Office Locations

Cue Biopharma has an office in Cambridge
Cambridge, MA, US (HQ)
21 Erie St
Show all (1)

Cue Biopharma Financials and Metrics

Cue Biopharma Revenue

Cue Biopharma's revenue was reported to be $3.15 m in FY, 2020
USD

Revenue (FY, 2020)

3.2m

Net income (FY, 2020)

(44.8m)

EBIT (FY, 2020)

(45.0m)

Market capitalization (23-Sept-2021)

445.5m

Closing stock price (23-Sept-2021)

14.9

Cash (31-Dec-2020)

74.9m

EV

377.8m
Cue Biopharma's current market capitalization is $445.5 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

3.5m3.2m

General and administrative expense

425.1k2.0m4.3m11.3m12.7m14.7m

R&D expense

1.5m5.7m18.9m28.5m27.5m33.5m

Operating expense total

1.9m7.7m23.2m39.8m40.2m48.2m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

1.1m900.0k1.1m

General and administrative expense

1.7m2.2m2.9m3.4m3.4m4.0m3.9m

R&D expense

5.8m5.4m10.3m8.4m6.9m9.9m8.1m

Operating expense total

7.5m7.6m13.2m11.8m10.3m13.9m12.0m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

6.4m14.9m63.5m10.5m44.3m74.9m

Accounts Receivable

754.9k1.4m

Prepaid Expenses

51.4k162.4k403.4k1.3m860.1k1.2m

Current Assets

6.5m15.1m65.1m40.6m61.0m87.5m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

53.1m45.7m15.8m21.9m24.3m31.4m23.4m59.7m

Accounts Receivable

522.0k610.0k605.0k1.2m

Prepaid Expenses

884.0k3.5m1.4m1.0m1.0m1.0m1.9m2.2m

Current Assets

55.9m49.3m40.6m32.0m29.9m33.0m51.2m88.4m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(1.9m)(7.7m)(23.2m)(39.0m)(36.7m)(44.8m)

Depreciation and Amortization

44.8k202.1k419.6k760.0k810.8k1.1m

Accounts Payable

177.8k372.1k561.6k376.1k(1.2m)741.3k

Cash From Operating Activities

(1.7m)(6.0m)(12.2m)(26.4m)(30.8m)(32.5m)
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

(7.5m)(14.8m)(27.4m)(11.3m)(20.8m)(27.8m)(12.8m)(23.7m)

Depreciation and Amortization

167.0k362.0k556.0k205.0k410.0k605.0k263.0k535.0k

Accounts Payable

(390.0k)(1.1m)(662.0k)858.0k254.0k(857.0k)717.0k406.0k

Cash From Operating Activities

(9.8m)(16.2m)(22.5m)(8.5m)(15.2m)(24.4m)(10.9m)(17.8m)
USDFY, 2015

Financial Leverage

1.1 x
Show all financial metrics

Cue Biopharma Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Cue Biopharma Online and Social Media Presence

Embed Graph

Cue Biopharma News and Updates

Cue Biopharma Granted U.S. Patents on Lead Clinical Program Novel Drug Product Candidate CUE-101

Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio Patents Further Strengthen and Enhance Intellectual Property (IP) Portfolio

Cue Biopharma to Present at Two Upcoming Investor Healthcare Conferences

CAMBRIDGE, Mass., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that…

Cue Biopharma Reports Second Quarter 2021 Results, Recent Data Updates of CUE-101 Phase 1 Dose Escalation and Expansion Study, Platform Progress and Business Highlights

CAMBRIDGE, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the patient’s body, provided a business and clinical progre…

Cue Biopharma to Present Corporate Update at the Upcoming BTIG Virtual Biotechnology Conference

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that …

Cue Biopharma to Present at the Upcoming JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., June 14, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that …

Cue Biopharma Announces First Patient Dosed in Part B Patient Expansion of CUE-101 Phase 1 Monotherapy Trial in HPV+ Second Line and Beyond HNSCC

CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells directly within the patient’s body, announced today that …
Show more

Cue Biopharma Blogs

Senior Associate Scientist/Scientist TCR Core Lab

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer, infectious disease and autoimmune disease. Cue Biopharma is a high growth co…

Senior Scientist, Protein Formulation Development

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer, infectious disease and autoimmune disease. Cue Biopharma is a high growth co…

Senior Scientist/Principal Scientist, Protein Purification Process Development

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer, infectious disease and autoimmune disease. Cue Biopharma is a high growth co…

Senior/Principal Scientist, Upstream Cell Culture Process Development

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer, infectious disease and autoimmune disease. Cue Biopharma is a high growth co…

Associate Director / Director Translational Medicine

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer, infectious disease and autoimmune disease. Cue Biopharma is a high growth co…

Senior Associate Scientist/Scientist, Protein Discovery

The Company Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer, infectious disease and autoimmune disease. Cue Biopharma is a hi…
Show more

Cue Biopharma Frequently Asked Questions

  • When was Cue Biopharma founded?

    Cue Biopharma was founded in 2015.

  • Who are Cue Biopharma key executives?

    Cue Biopharma's key executives are Dan Passeri, Frank Morich and Anish Suri.

  • How many employees does Cue Biopharma have?

    Cue Biopharma has 46 employees.

  • What is Cue Biopharma revenue?

    Latest Cue Biopharma annual revenue is $3.2 m.

  • What is Cue Biopharma revenue per employee?

    Latest Cue Biopharma revenue per employee is $68.6 k.

  • Who are Cue Biopharma competitors?

    Competitors of Cue Biopharma include ANI Pharmaceuticals, Sorrento Therapeutics and Aerie Pharmaceuticals.

  • Where is Cue Biopharma headquarters?

    Cue Biopharma headquarters is located at 21 Erie St, Cambridge.

  • Where are Cue Biopharma offices?

    Cue Biopharma has an office in Cambridge.

  • How many offices does Cue Biopharma have?

    Cue Biopharma has 1 office.